

Phase I Trials of Preventive HIV/AIDS Vaccines Worldwide (August 2007)

Including all trials that started in 2006 or 2007

DVP-1

Start date: May 2007 Sponsor: St. Jude's Children's Research Hospital
Trial Site(s): US Participants: 20
Vaccine(s): Prime-boost regimen with PolyEnv, EnvPro, EnvDNA
Clade: A, B, C, D, E

VRC 012

Start date: May 2007 Sponsor: NIAID, VRC
Trial Site(s): US Participants: 35
Vaccine(s): HIV-1 adenovirus vector vaccine VRC-HIVADV027-00-WP;
dose escalation and prime-boost with an HIV-1 adenovirus vector vaccine.
VRC-HIVADV038-00-VP
Clade: A

DH0-0586

Start date: October 2006 Sponsor: ADARC, IAVI
Trial Site(s): US Participants: 8
Vaccine(s): ADMVA with env/gag-pol, nef-tat
Clade: C

HPTN 027

Start date: October 2006 Sponsor: Makerere University, Johns Hopkins
University
Trial Site(s): Uganda Participants: 50
Vaccine(s): Canarypox viral vector with env and gag-pol
Clade: B

C86P1

Start date: September 2006 Sponsor: SGUL, Richmond Pharmacology,
Novartis Vaccines
Trial Site(s): UK Participants: 31
Vaccine(s): Prime: HIV gp140 with LTK63, Boost: HIV gp140 with MF59
Clade: B

VRC 011

Start date: April 2006 Sponsor: NIAID, VRC
Trial Site(s): US Participants: 60
Vaccine(s): DNA vaccine with gag, pol, nef + env or Adenovirus vector
with gag, pol + env
Clade: A, B, C

HVTN 065

Start date: April 2006 Sponsor: DAIDS, HVTN, VRC, GeoVax
Trial Site(s): US Participants: 120
Vaccine(s): Prime: DNA plasmid with gag, pro, RT, env, tat, rev, vpu;
Boost:

MVA vector with gag, pol, env
Clade: B

HVRF-380-131004

Start date: March 2006 Sponsor: Moscow Institute of Immunology,
Russian Federation Ministry of Education and
Science
Trial Site(s): Russian Federation Participants: 15
Vaccine(s): VICHREPOL with polyoxidonium adjuvant
Clade: B

IAVI D001

Start date: February 2006 Sponsor: IAVI, Therion
Trial Site(s): India Participants: 32
Vaccine(s): Modified vaccinia Ankara (MVA) viral vector with env, gag, tat-
rev, nef-RT
Clade: C

HVTN 064

Start date: January 2006 Sponsor: DAIDS, HVTN, Pharmexa Epimmune
Trial Site(s): US, Peru Participants: 120
Vaccine(s): Recombinant protein vaccine EP-1043 with gag, pol, vpr, nef
and DNA vaccine EP HIV-1090 with protein containing T-helper epitopes
from env, gag, pol, vpu
Clade: B

HVTN 068

Start date: February 2006 Sponsor: DAIDS, HVTN, VRC
Trial Site(s): US Participants: 66
Vaccine(s): Adenovirus vector with gag, pol + env or DNA vaccine with gag,
pol, nef + env followed by adenovirus boost
Clade: B; A, B, C

HCIS 02

Start date: January 2006 Sponsor: Karolinska Institute, Swedish
Institute for Infectious Disease Control,
USMHRP
Trial Site(s): Sweden Participants: 38
Vaccine(s): Modified vaccinia Ankara (MVA) viral vector with env, gag and
pol to volunteers from HVIS 01
Clade: A, E

Source: Reprinted from "AVAC Report 2007Resetting the Clock,"
published by the AIDS Vaccine Advocacy Coalition. www.avac.org/
(www.avac.org).